---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-031337"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T15:15:00.145073+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PepGen voluntarily pauses Phase 2 CONNECT2-EDO51 study; awaits 10 mg/kg data from CONNECT1

## Summary
- Temporarily pauses CONNECT2-EDO51 in DMD until review of 10 mg/kg data from ongoing CONNECT1-EDO51 study.
- No new safety issues observed in PGN-EDO51 program since safety update on January 23, 2025.
- CONNECT1 10 mg/kg cohort fully enrolled; data expected in third quarter of 2025.
- Resources focused on completing CONNECT1 and advancing FREEDOM-DM1 studies in myotonic dystrophy type 1.
- CEO states pause allows gathering additional safety data and potential improvement of CONNECT2 design.

## SEC filing metadata
- accession: 0000950170-25-031337
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017025031337/0000950170-25-031337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017025031337/pepg-20250304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-031337
- JSON: https://secwatch.observer/filing/0000950170-25-031337.json
- Plain text: https://secwatch.observer/filing/0000950170-25-031337.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.